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Abstract
Introduction: Coronary artery disease progression after primary coronary artery bypass grafting
may, beside classical atherosclerosis risk factors, be depending on genetic predisposition.
Methods: We investigated 192 CABG patients (18% female, age: 60.9 ± 7.4 years). Clinically
cardiac adverse events were defined as need for reoperation (n = 88; 46%), reintervention (n = 58;
30%), or angina (n = 89; 46%). Mean follow-up time measured 10.1 ± 5.1 years. Gene
polymorphisms (ApoE, NOS3, LIPC, CETP, SERPINE-1, Prothrombin) were investigated
separately and combined (gene risk profile).
Results: Among classical risk factors, arterial hypertension and hypercholesterinemia significantly
influenced CAD progression. Single ApoE, NOS3 and LIPC polymorphisms provided limited
information. Patients missing the most common ApoE  ε3 allele (5,2%), showed recurrent
symptoms (p = 0,077) and had more frequently reintervention (p = 0,001). NOS3 a allele was
associated with a significant increase for reintervention (p = 0,041) and recurrent symptoms (p =
0,042).
Homozygous LIPC patients had a higher reoperation rate (p = 0.049).
A gene risk profile enabled us to discriminate between faster and slower occurrence of cardiac
adverse events (p = 0.0012).
Conclusion:  Single  APOE, LIPC and  NOS3  polymorphisms permitted limited prognosis of
cardiac adverse events in patients after CABG. Risk profile, in contrast, allowed for risk
stratification.
Background
Coronary artery disease (CAD) is a multifactorial disor-
der, accounts for roughly one-half of all cardiovascular
deaths, and is a major cause of morbidity and mortality.
Classical risk factors for CAD such as smoking or altera-
tions in lipid metabolism are well known for decades to
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increase the incidence [1,2]. Patient counselling and med-
ical therapy of risk factors have become the basis for sec-
ondary CAD prevention after primary coronary artery
bypass grafting (CABG). Appearance of cardiac adverse
events after primary CABG is frequent and leads to recur-
rent angina, myocardial infarction, and the need for
reintervention.
Apolipoproteins play a major role in lipid metabolism.
They transfer water insoluble lipids in their soluble state
and enable lipid transport mechanisms. Furthermore,
they may act as ligands for lipid receptors. Apolipoprotein
E (ApoE) is a ligand for the low density lipoprotein (LDL)
receptor and regulates catabolism of lipoproteins. ApoE is
also the main protein component of the very low density
lipoproteins (VLDL) and high density lipoproteins
(HDL). ApoE polymorphisms generate more than 10 per-
cent of the interindividual difference of plasma choles-
terol. There are several forms of ApoE. Among them,
ApoE4 has a higher and ApoE2 much lower affinity to the
LDL receptor. That is the reason, why lipoproteins of ε4
carriers disappear much faster from plasma. Consecu-
tively, that leads to downregulation of hepatic LDL recep-
tor, resulting in rise of plasma LDL cholesterol. Therefore,
ApoE4 may potentially be considered atherogenic, while
ApoE2 seems to show a protective effect. That explains the
higher cardiovascular risk of ε4 carriers [3]. Baroni et al.,
demonstrated correlation between ApoE4 polymorphism
and the incidence of CAD [4].
Dysfunction of the vascular endothelium, defined as
impaired nitric oxide (NO) activity, may also play a sub-
stantial role in the initiation and progression of athero-
sclerosis [5,6]. Most important in this regard appears to be
activity or quantity of the enzyme endothelial nitric oxide
synthase (eNOS). Several single nucleotide polymor-
phisms (SNPs) have been described in the NOS3 gene and
some of them have been associated with cardiovascular
diseases such as 786T/C and 894G/T polymorphism. The
786 CC allele is connected to a reduced gene transcription
and probably connected to a decreased NO production. C
allele seems to be associated to a higher atherosclerotic
risk and coronary spasm [6]. Wang et al. could demon-
strate a significantly higher incidence of the rare
homozygous eNOS 4a allele in patients with significantly
stenosed peripheral arteries. If 894T allele is present in
894G/T polymorphism eNOS activity may be impaired
[5]. This polymorphism may also influence NO release of
thrombocytes. We investigated the insertion/deletion pol-
ymorphism in intron 4. It is located on chromosome
7q36.
Hepatic lipase (LIPC) is a lipolytic enzyme synthesized in
hepatocytes playing a major role in HDL metabolism. It
takes part in hydrolysis of triacylglycerides and phosphol-
ipids of HDL2 into antiatherogenic, cholesterol rich HDL3
as well as catalysation of hydrolysis of big triacylglyceride
rich LDL into small, compact, and atherogenous LDL par-
ticles. There is a positive correlation between concentra-
tion of small, compact LDL and LIPC activity [7].
The LIPC gene is located on chromosome 15 (q21-q23).
De Andrade et al., showed a significant correlation
between male carriers of a LIPC  polymorphism and a
higher CAD risk independently of conventional risk fac-
tors. The C202G polymorphism may also be associated
with higher triglyceride and lower HDL levels [7].
The influence of the classical risk factors and of genetic
polymorphisms, whose protein products play a role in
lipid metabolism, coagulation, and nitric oxide metabo-
lism, on the appearance of cardiac adverse events in
patients after CABG, who receive contemporary medical
treatment, is still unknown.
We hypothesized that CAD risk factors, perioperative
parameters, and a genetic predisposition determine the
occurrence of adverse cardiac events after primary CABG
in individual patients. The hypothesis was tested by retro-
spectively investigating a group of patients, which under-
went primary CABG at our institution more than five
years ago. Genetic polymorphisms known to be risk fac-
tors for CAD were determined in this patient cohort.
Reoperations, reinterventions, and angina at follow-up
served as clinically relevant cardiac adverse events.
Methods
Patients
One-hundred-and-ninety two patients, who underwent
their first isolated CABG between 1979 and 1999, were
investigated. Demographic data and medical therapies at
the time of prior CABG are listed in Table 1. All patients
made a follow-up visit at our Department between March
and October 2007. After written informed consent was
given, EDTA blood was drawn for genetic analyses. Reop-
eration for CAD, reintervention (PTCA and/or stenting
and/or hospital admission for myocardial infarction),
angina at the time of follow-up, and a combined endpoint
of the three previous ones, further referred to as recurrent
symptoms were defined as cardiac adverse events. Most
patients (n = 137; 71%) had either a second CABG (n =
88; 46%; 9.3 ± 3.3 years p.o.), a reintervention (n = 58;
30%; 10.4 ± 5.9 years p.o.), or suffered from an angina at
follow-up (n = 89; 46%; 12.6 ± 5.8 years p.o). All patients
received medical therapy at follow-up. Aspirin (87%),
beta blockers (70%), statins (50%), ACE inhibitors
(35%), and calcium antagonists (24%) were most com-
monly prescribed. Patients with progression of CAD were
more likely to receive intensified therapy with ACE inhib-
itors (p = 0.04), and beta blockers (p = 0.008).Journal of Cardiothoracic Surgery 2009, 4:46 http://www.cardiothoracicsurgery.org/content/4/1/46
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Genetic analyses
Polymorphisms in genes coding for factors involved in
lipid metabolism: apolipoprotein E (APOE) [4,8], hepatic
lipase (LIPC) [7], and cholesteryl ester transfer protein
(CETP) [9], the NO-donor system: endothelial NO syn-
thase (NOS3) [6], and the coagulation system: plasmino-
gen activator inhibitor 1 (SERPINE-1) [10], coagulation
factor V (F5) [11], and coagulation factor II (prothrombin
(F2)) [12] previously described to play a role in the devel-
opment of CAD were chosen. The genes investigated, their
polymorphisms, function as well as the primer sequences
are shown in Additional File 1.
Restriction Fragment Length Polymorphism (RFLP) 
Analysis
To investigate the selected seven polymorphisms, restric-
tion fragment length polymorphism (RFLP) analysis was
used. The patients genomic DNA was isolated from a 200-
μl aliquot by means of the QIAamp blood mini kit (Qia-
gen, Hilden, Germany). The PCR reactions contained 5 μl
PCR buffer (ABgene, Hamburg, Germany), 5 μl dNTPMix
(Fermentas Life Sciences, St. Leon-Rot, Germany) as well
as 1 μl forward and 1 μl backward primer (400 nmol;
Thermo Electron Corporation, Ulm, Germany) in a vol-
ume of 50 μl containing about 150–200 ng of genomic
DNA. Depending on the specific polymorphism, the PCR
was comprised of an initial denaturation step (15 minutes
at 95°C), 35 to 40 cycles of 95°C for 20 to 30 seconds, 58
to 72°C for 20 to 30 seconds, and of 72°C for 30 sec).
The restriction digests were performed in a 10-μl volume
containing the restriction enzyme (Fermentas Life Sci-
ences, St. Leon-Rot, and New England BioLabs, Frankfurt
am Main, Germany), 1× restriction buffer, and the PCR
product. The digests were incubated overnight at 37°C
and analysed by electrophoresis in a 1,5–3% agarose gel
which was subsequently stained with ethidium bromide.
Details of the polymorphisms analyzed are summarized
in Additional File 1.
Risk profile
Because SNPs had a relatively low prevalence in our lim-
ited patient cohort and CAD is a multifactorial disease, we
constructed a risk profile. Carriers of the risk profile were
defined as having one of the following polymorphisms:
hetero- or homozygous for the variants of eNOS 4ab, the
ApoE allele combination 2/4 or 4/4, homozygous expres-
sion of LIPC variant, homozygous expression of the CETP
variant, and hetero- or homozygosity for the prothrombin
G20210A variant. Patients had to be homozygous for PAI-
1 5G insertion.
Statistics
For statistical data analysis Microsoft® EXCEL 2002 and
SPSS for Windows (Version 12.0, SPSS Inc., Chicago, IL,
USA) were used. The primers for the PCR analyses were
designed with the help of the computer program
"PrimerExpress" (Applied Biosystems).
Values are expressed as mean and standard deviation of
mean. The Student's t-Test was used to compare absolute
quantitative values. Angina was censored at the day of fol-
low-up, because a precise onset of angina could not be
determined. Freedom from reoperation, reintervention,
and the combined endpoints (reoperation, reinterven-
tion, or angina at follow-up) were calculated by the actu-
arial method and tested with the log-rank test. Every
univariate parameter reaching or approaching signifi-
cance (p < 0.2) was then tested in a Cox multivariate
model using the conditional backward method. P < 0.05
was considered significant.
Results and discussion
Results
Preoperative risk factors of CAD and occurrence of cardiac adverse 
events
Documented risk factors at the time of primary CABG had
limited impact on the occurrence of cardiac adverse events.
Arterial Hypertension was evident at the time of primary
surgery in 73% of our patients and did significantly
Table 1: Demographics of patients and medical therapy at the 
time of primary CABG
Patients [#] 192
Female [#] 34 (18%)
Age [Years] 60.9 ± 7.4
Ejection fraction [%] 63.0 ± 14.5
NYHA Class 3.0 ± 1.0
Bypasses [#] 2.4 ± 1.0
Left internal thoracic artery grafts [#] 1.0 ± 0.5
Saphenous Vein Grafts [#] 1.5 ± 1.0
Additional Grafts [#] 0.4 ± 0.5
Aspirine Intake [%] 75
Beta blockers [%] 70
Statins [%] 50
ACE Inhibitors [%] 35
Calcium Channel Blockers [%] 24Journal of Cardiothoracic Surgery 2009, 4:46 http://www.cardiothoracicsurgery.org/content/4/1/46
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increase the risk of progression in the sense of reinterven-
tion (p = 0.04). Eighty two percent of our patients showed
hypercholesterinemia at primary CABG. It tended (p =
0.073) to increase the risk of recurrent symptoms. Just
17% of the investigated CABG patients suffered from dia-
betes. Significant results are shown in Table 2.
Perioperative parameters and occurrence of cardiac adverse events 
(Table 3)
Perioperative parameters demonstrate selection bias for
future therapy. Elderly patients (>60 years at primary
CABG) were less likely to undergo reoperation (p = 0.05),
but tended to be more often selected for reinterventions
(p = 0.15). Moreover, patients with 3 or more bypasses
had less reoperations than patients with 2 or less (p =
0.005).
Gene polymorphisms and occurrence of cardiac adverse events 
(Table 4)
Out of seven polymorphisms, the following single gene
polymorphisms showed significant results and therefore,
will results will be restricted to these single polymor-
phisms: Mutation of eNOS increased the risk for reinter-
ventions (0.041) and for recurrent symptoms (p = 0.042).
A similar effect on reinterventions (0.001) and recurrent
symptoms (0.077) was observed in patients missing the
most common type 3 allele of ApoE. Patients homozygous
for the LIPC mutation had a higher incidence of reopera-
tions (p = 0.049).
Distribution of the three ApoE alleles
Detailed results of the ApoE alleles are demonstrated in Table
5 Patients, who miss the most common allele ε3 of ApoE
(5.2%), showed recurrent symptoms (p = 0.077) and had
more frequently to undergo a reintervention (p = 0.001).
Distribution of eNOS 4ab polymorphism
The homozygous genotype bb (wild type = insertion/
insertion) of eNOS 4ab insertions/deletion polymor-
phisms was found in 73.4%. The rare allele a with dele-
tion showed a level of 26.6% of patients, but only 1.6%
had homozygous genotype aa (deletion/deletion) and
25% had heterozygous genotype ab (deletion/insertion).
Results are depicted in Table 6.
The a allele of NOS3 was associated with a significantly
risk increase of reintervention (p = 0.041) and recurrent
symptoms (p = 0.042). Only 5.1% of patients with allel a,
were free of symptoms after 15 years. Carrier of hetero-
zygous expression had a 30% higher likelihood of reoper-
ation, meanwhile patients with homocygous expression
were 30% more likely, not to undergo a reoperation (p =
0,04).
Distribution of LIPC genotypes in regard to C→G exchange at codon 
202
Analyses showed a higher incidence of reoperation in
patients with homozygous genotype (p = 0.049). Table 7
shows the distribution of LIPC genotypes in our patient's
population.
Risk profile and occurrence of cardiac adverse events (Figure 1)
Patients with the risk profile had significantly more reop-
erations (0.012) and were more likely to have recurrent
symptoms (0.0012). The incidence of percutaneous inter-
ventions were not different among groups (p = 0.38).
However, multivariate Cox regression analysis revealed
that only the risk profile had significant impact on the
progression of CAD (p = 0.004).
Discussion
In our study, we investigated a subset of gene polymor-
phisms known from other investigations as suspects in the
development of CAD. Occurrence of cardiac adverse
events after primary CABG was significantly influenced by
genetic polymorphisms; among the seven evaluated poly-
morphisms  ApoE  and  eNos  variants had the highest
impact on reoperations and reinterventions.
ApoE Polymorphism
Several studies focused on the effects of ApoE after cardi-
opulmonary bypass and reported a higher incidence of
inflammation [8] and nephropathy [13] in patients with
the E4 allele; depending on the trial more or less neuro-
logical sequelae were seen with the E2 allele [14,15]. In
Table 2: Preoperative arterial hypertension and hypercholesterinemia in correlation to occurrence of cardiac adverse events
Freedom from [%] at 
Factor Definition n  Outcome 5 years 10 years 15 years p
Hypertension Yes 140 Reintervention 90.6 81.7 66.4 0.04
No 52 95.2 88.9 88.9
Hypercholesterinemia Yes 159 Combined 84.4 46.2 10.0 0.073
No 33 96.7 76.7 18.5
Significant differences are in italics (p < 0.05) print.Journal of Cardiothoracic Surgery 2009, 4:46 http://www.cardiothoracicsurgery.org/content/4/1/46
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Kuukasjärvi et al. [16] investigated the ApoE E4 allele and
found, in contrast to most of the studies, this polymor-
phism not to be a predictor for reoperation. Interestingly,
in our study patients without the most frequent allele E3,
thus only having the risk alleles E2 and E4, had a more
aggressive type of CAD. In regard to the total population,
there is no other gene product, which has such a big influ-
ence on the individual cholesterin level such as ApoE.
Especially the ε4 allele is increasing the plasma level of
LDL. In various investigations ApoE was associated with a
higher incidence of atherosclerosis. Baroni et al conducted
a study with 6 polymorphisms influencing the lipid sys-
tem (ApoE, ApoAI, ApoCIII, ApoB, lipoprotein lipase LPL und
LIPC [4]. One hundred and two patients with diagnosed
CAD were enrolled and 104 healthy patients served as
controls. Significant difference between CAD and healthy
patients could be demonstrated for Apolipoprotein E,
ApoB and HL. ApoE ε4 allele was associated with a mani-
fest CAD. Results of our study were similar: patients with
deletion of the most common allele ε3 that means they
carry the rare combination of either ε2/4 or ε4/4 (isoform
ε2/2 is extremely rare) had more frequently to undergo a
reintervention. After incidence is so low (2–3% of general
population), evaluation is limited. Therefore, a higher
number of patients would be desirable.
eNOS 4ab
The investigated eNOS variant has been associated with a
higher susceptibility to coronary lesions in smokers and
NO metabolites were 20% decreased in patients with the
4aa variant [5]. For endothelial NOS at least 4 frequent
polymorphisms (G894T, Glu298Asp, T786C, and the one
used in this study) are well established and described to
be risk factors for CAD. The argument of having no spe-
cific hypothesis to investigate just one and not all other
polymorphisms is valid. Further more, some authors see
differences in subgroups, i.e. smokers vs. non smokers
and young adults. These oppositional results are fre-
quently seen in genetic studies and may be due to the
multi factorial origin of the disease. For instance, in japa-
nese and caucasians similar patterns of eNOS alleles were
observed [17], but in afroamericans the incidence is gen-
erally much lower. Especially environmental factors are
difficult to record such as smoking, which is particularly
Table 3: Perioperative parameters and occurrence of cardiac adverse events
Freedom from [%] at
Factor Definition n Outcome 5 years 10 years 15 years p
Age < 60 years 110 Reoperation 95.3 65.7 19.9 0.052
> 60 years 82 93.8 78.7 46.3
< 60 years 110 Reintervtion 93.2 88.6 77.4 0.15
> 60 years 82 90.8 79.1 58.1
# of bypasses < 3 110 Reoperation 91.6 61.8 24.8 0.005
≥ 3 82 98.7 81.6 22.2
Significant differences are in italics (p < 0.05) or bold (p < 0.01) print.
Table 4: Genetic Polymorphisms and occurrence of cardiac adverse events
Freedom from [%] at
Factor Definition n Outcome 5 years 10 years 15 years P
eNos  bb 141 Reintervention 93.9 88.7 75.9 0.041
4ab aa/ab 51 87.5 67.9 62.7
bb 141 Combined 89.3 56.0 13.2 0.042
aa/ab 51 80.4 40.6 5.1
ApoE 2 3/3 3/3 4 182 Reintervention 92.3 84.5 75.1 0.001
2 4/4 4 10 90.0 64.3 32.1
LIPC WW/WM 144 Reoperation 96.4 74.6 27.5 0.049
MM 48 89.5 54.5 9.9
See Additional File 1for abbreviations of polymorphisms. M: Mutation; W: Wildtype. Significant differences are in italics (p < 0.05) or bold (p < 0.01) 
print.Journal of Cardiothoracic Surgery 2009, 4:46 http://www.cardiothoracicsurgery.org/content/4/1/46
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important in eNOS. In our study, the a allele of eNOS 4ab
polymorphism was associated with a significantly higher
risk for reintervention and recurrent symptoms.
LIPC C202G
Enzyme activity of hepatic lipase plays a major role in reg-
ulating the lipid metabolism. In the above mentioned
study from Baroni et al. in carriers of the g allele of C202G
mutation, a decreased level of HDL cholesterol and
increased level of triglycerides was observed [4]. Interest-
ingly, the authors found another independent factor
regarding clinical endpoints: carrier of homo- or hetero-
zygous g allele had significantly more frequently a second
adverse event. Also our results demonstrate a similar
course: patients with homozygous expression of the g
allele (n = 48) needed more frequently a reoperation. For
this mutation, Murtomaki et al, demonstrated a binding
imbalance towards additional LIPC polymorphisms such
as L334F, T457T and C480T). Last is related to a low LIPC
activity in CAD patients [18]. That means that C202G
mutation is a simple marker for additional LIPC polymor-
phisms and their mutations.
Recently Taylor and associates [19] reported on the influ-
ence of lipoprotein lipase locus on the progression of
atherosclerosis in coronary artery bypass grafts and identi-
fied the LPL-HINDIII 2/2 genotype as an independent risk
factor.
Risk Profile
After single mutations had a relatively low prevalence in
our limited patient cohort and CAD is a multifactorial dis-
ease we constructed a gene risk profile according to the
definitions. It was a combination of the alleles with the
highest incidence of either one of clinical endpoints:
Included was hetero- or homozygous a-allele of eNOS 4ab
polymorphism, because patients showed a significantly
higher risk to get a rentervention or recurrent symptoms.
Regarding the ApoE they had to carry ε4 allele, that means
ε2/4 or ε4/4, as it is considered to be potentielly atherog-
enous, was we could also demonstrate. Homozygous car-
riers of hepatic lipase were prone to undergo a reoperation
and recurrent symptoms. That's why part of the risk gene
profile was homozygous expression of the G allele.
Homozygous expression of CETP gene polymorphism
was included. Additionally, hetero- or homozygous vari-
ants of G20210A mutation was chosen, because only 50
and 0% carriers of these variants were free from recurrent
symptoms after 10 and 15 years, respectively. However, a
simple gene risk profile constructed out of 7 randomly
chosen polymorphisms was more predictive for the
advancement of CAD than any cluster of classical risk fac-
tors.
Certainly medical therapy, particularly lowering of low-
density lipoprotein cholesterol levels, has been proven to
reduce the advancement of CAD after CABG [20]. Due to
the design of our retrospective study, we were unable to
prove the beneficial effects of medical therapy, because
therapy after primary CABG was determined by the cardi-
ologist and patients with recurrent symptoms received
intensified medical therapy. In the investigated patient's
cohort 87% received Aspirine, 70% were given beta block-
ers, 82% of patients received statins, 35% ACE inhibitors
and 24% took calcium antagonists postoperatively. Like-
wise, the role of classical risk factors on the CAD progres-
sion is difficult to interpret. Risk factors at the time of
primary CABG were medically treated as described above;
patients stopped smoking and started training programs.
Therefore, these classical risk factors lost partially their
predictive value. Obviously, we investigated only long-
term survivors of CABG surgery, who were willing to
cooperate. This selection bias may also limit our results.
Table 5: Distribution of the three ApoE alleles
ApoE ε2/2 ε2/3 ε3/3 ε3/4 ε4/4 ε4/2 Total
Number[n] 0 22 114 46 2 8 192
Percentage[%] 0 11,5 59,4 24,0 1,0 4,2 100
Patients, who miss the most common allele ε3 of ApoE (5,2%), 
showed recurrent symptoms (p = 0,077) and had more frequently to 
undergo a reintervention (p = 0,001).
Table 6: Distribution of eNOS 4ab polymorphism
eNOS bb ab aa Total
Number[n] 141 48 3 192
Percentage[%] 73,4 25,0 1,6 100
The homozygous genotype bb (wild type = insertion/insertion) of 
eNOS 4ab insertions/deletion polymorphisms was found in 73,4%. 
The rare allele a with deletion showed a level of 26,6% of patients, but 
only 1,6% had homozygous genotype aa (deletion/deletion) and 25% 
had heterozygous genotype ab (deletion/insertion).
Table 7: Distribution of LIPC genotypes in regard to C to G 
exchange
LIPC CC CG GG Total
Number[n] 49 95 48 192
Percentage[%] 25,5 49,5 25,0 100
The homozygous genotype bb (wild type = insertion/insertion) of 
eNOS 4ab insertions/deletion polymorphisms was found in 73,4%. 
The rare allele a with deletion showed a level of 26,6% of patients, but 
only 1,6% had homozygous genotype aa (deletion/deletion) and 25% 
had heterozygous genotype ab (deletion/insertion).Journal of Cardiothoracic Surgery 2009, 4:46 http://www.cardiothoracicsurgery.org/content/4/1/46
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Knowledge of gene polymorphisms in the era of genomics
and their influence on outcome in cardiac surgery is rap-
idly growing. However, most studies investigated the
acute effects of polymorphisms outcome during the post-
operative phase. Data on the progression of CAD after pri-
mary CABG is rare.
This study is only preliminary, because of its limitations in
patient sample size as well as number and choice of inves-
tigated polymorphisms. More investigations are war-
ranted and will most likely improve the predictive value of
polymorphism tests. We proved the concept, that risk
stratification by a simple gene test for the future advance-
ment of CAD after primary CABG is possible. The concept
is intriguing, because the detected gene variants give clues
to the individual pathophysiology in every single patient
in this multifactorial disease [18]. Therefore, this cheap
diagnostic tool may hopefully lead to an individualized
secondary prevention after primary CABG.
Conclusion
Classical preoperative risk factors provide little informa-
tion on appearance of cardiac adverse events, probably
because they are so very common among CABG patients.
Additionally, most patients were medically treated. Single
gene polymorphisms of patients, in the era of whole
genome scans, allow a limited prognosis for CAD progres-
sion after primary CABG. Risk gene profiles enable risk
stratification of CAD progression. They may have the
potential to individualize therapy in the future, due to
pathophysiological links. Further gene polymorphisms
have to be investigated to improve risk stratification.
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Risk profile and occurrence of cardiac adverse events Figure 1
Risk profile and occurrence of cardiac adverse events. Out of the seven investigated gene polymorphisms, six were 
combined for a risk profile (see text). Patients with the risk profile had significantly more reoperations (0.012) and were more 
likely to have recurrent symptoms (0.0012). The incidence of interventions (PTCA, stent) were not different among the groups 
(p = 0.38). However, multivariate Cox regression analysis revealed that only the risk profile had significant impact on the inci-
dence of cardiac adverse events (p = 0.004).
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Additional file 1
Investigated genes, their polymorphisms and function, primer and 
primer sequences. Polymorphisms in genes coding for apolipoprotein E 
(APOE) [4,8], hepatic lipase (LIPC), cholesteryl ester transfer protein 
(CETP), endothelial NO synthase (NOS3), and plasminogen activator 
inhibitor 1 (SERPINE1), coagulation factor V (F5), and coagulation fac-
tor II (prothrombin (F2)) were chosen. Details of the polymorphisms are 
summarized in this additional file 1. Abbreviations: A: Arginin; C: 
Cytosin; G: Guanin; T: Thymin; HDL: high density lipoprotein; LDL: low 
density lipoprotein; VLDL: very low density lipoprotein
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